Fam-Trastuzumab Deruxtecan-Nxki

DRUG4 trials

Sponsors

Strata Oncology, Enliven Therapeutics, QuantumLeap Healthcare Collaborative, Memorial Sloan Kettering Cancer Center

Conditions

AdenocarcinomaAdenocarcinoma of ColonAdenocarcinoma of the ColonAdenocarcinoma of the RectumAdvanced Solid TumorCancerColo-rectal CancerColon Cancer

Phase 1

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

Active, not recruitingNCT05650879

Enliven TherapeuticsHER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation +1

Start: 2023-03-20End: 2026-07-31Target: 198Updated: 2025-07-15

PRE-ISPY Phase I/II Oncology Platform Program

RecruitingNCT05868226

QuantumLeap Healthcare CollaborativeHER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer +29

Start: 2023-02-15End: 2031-12-30Target: 280Updated: 2026-09-02

Phase 2

StrataPATH™ (Precision Indications for Approved Therapies)

TerminatedNCT05097599

Strata OncologyCancer, Advanced Solid Tumor

Start: 2022-04-29End: 2024-06-12Updated: 2025-01-08

A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer

Not yet recruitingNCT07691489

Memorial Sloan Kettering Cancer CenterColorectal Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum

Start: 2026-08-01End: 2029-06-01Target: 27Updated: 2026-07-09

Related Papers

Abstract PS5-01-24: Evorpacept (ALX-148) combined with trastuzumab deruxtecan in patients with HER2 positive/HER2low metastatic breast cancer (mBC): results from the PRE-ISPY phase Ib trial

Clinical Cancer Research2026-02-17

PRE-ISPY phase I/Ib oncology platform program (PRE-I-SPY-P1).

Journal of Clinical Oncology2024-06-011 citations

Abstract CT059: StrataPATHTM: a multicohort, non-randomized, open-label phase 2 trial to explore efficacy and safety of FDA-approved cancer therapies in novel biomarker-guided patient population

Cancer Research2023-04-14